Autoimmune Diseases  >>  prednisone delayed-release tablet  >>  Phase 3
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
prednisone delayed-release tablet / Generic mfg.
CAPRA-2, NCT00650078 / 2007-003508-36: Study to Assess the Safety and Efficacy of Modified-Release Prednisone (Lodotra®) Therapy in Patients With Active Rheumatoid Arthritis

Checkmark ACR-ARHP 2015: Rheumatoid arthritis (CAPRA-2)
Oct 2015 - Oct 2015: ACR-ARHP 2015: Rheumatoid arthritis (CAPRA-2)
Completed
3
350
US, Canada, Europe
MR prednisone, Placebo
Horizon Pharma Ireland, Ltd., Dublin Ireland
Rheumatoid Arthritis
05/09
05/09
NCT01821040 / 2011-002353-57: A Study Assessing the Efficacy and Safety of Lodotra® Compared to Prednisone IR in Subjects Suffering From PMR

Terminated
3
62
Europe
Lodotra®, Modified release prednisone, Prednisone IR (immediate release)
Mundipharma Research Limited
Polymyalgia Rheumatica
04/14
04/14
NCT00580229: A Safety Analysis of Oral Prednisone as a Pre-Treatment for Rituximab in Rheumatoid Arthritis.

Completed
2/3
50
US
prednisone, Rayos
University of South Florida
Rheumatoid Arthritis
12/10
12/11

Download Options